Antares Pharma (NASDAQ:ATRS): Q2 GAAP EPS of -$0.01 beats by $0.03.
Revenue of $28.43M (+100.8% Y/Y) beats by $6.24M.
Tuesday, August 6, 2019
Vericel EPS beats by $0.17, beats on revenue
Vericel (NASDAQ:VCEL): Q2 Non-GAAP EPS of -$0.05 beats by $0.17; GAAP EPS of -$0.45 misses by $0.07.
Revenue of $26.15M (+37.6% Y/Y) beats by $2.02M.
Sanofi-Regeneron Dupixent succeeds in late-stage pediatric dermatitis study
A Phase 3 clinical trial evaluating Regeneron Pharmaceuticals (NASDAQ:REGN) and development partner Sanofi’s (NASDAQ:SNY) Dupixent (dupilumab), added to standard-of-care topical corticosteroids, in children aged 6 – 11 years with severe atopic dermatitis met the primary and secondary endpoints.
At week 16, 33% of patients receiving 300 mg of Dupixent every four weeks and 30% of those receiving 100 or 200 mg of Dupixent every two weeks achieved clear or almost clear skin compared to 11% for placebo (p<0.0001 and p=0.0004, respectively).
70% of patients receiving Dupixent every four weeks and 67% of those receiving Dupixent every two weeks achieved 75% or greater skin improvement versus 27% for placebo (p<0.0001 for both).
The rates of adverse events in the Dupixent groups were 65% and 67%, respectively, compared to 73% for placebo.
Detailed results will be submitted for presentation at a future medical conference.
Dupixent is currently approved in the U.S. for adults and adolescents with atopic dermatitis or asthma and adults with rhinosinusitis with nasal polyposis.
Karyopharm Therapeutics EPS beats by $0.27, beats on revenue
Karyopharm Therapeutics (NASDAQ:KPTI): Q2 GAAP EPS of -$0.71 beats by $0.27.
Revenue of $9.49M (-52.3% Y/Y) beats by $9.4M.
BioCryst Pharmaceuticals EPS misses by $0.03, misses on revenue
BioCryst Pharmaceuticals (NASDAQ:BCRX): Q2 GAAP EPS of -$0.34 misses by $0.03.
Revenue of $1.45M (-88.4% Y/Y) misses by $0.57M.
Avanos Medical EPS beats by $0.03, beats on revenue
Avanos Medical (NYSE:AVNS): Q2 Non-GAAP EPS of $0.28 beats by $0.03; GAAP EPS of -$0.17 misses by $0.04.
Revenue of $172.2M (+7.0% Y/Y) beats by $0.18M.
Bausch Health Companies EPS misses by $0.02, revenue in-line
Bausch Health Companies (NYSE:BHC): Q2 Non-GAAP EPS of $1.04 misses by $0.02; GAAP EPS of -$0.49 misses by $0.18.
Revenue of $2.15B (+0.9% Y/Y) in-line.
Shares +3.77% PM.
Subscribe to:
Posts (Atom)